✦ LIBER ✦

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

✍ Scribed by Jonathan W. Friedberg; Jennifer L. Kelly; Donna Neuberg; Derick R. Peterson; Jeffery L. Kutok; Rabih Salloum; Thomas Brenn; David C. Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G. Rothberg; Jane Liesveld; Richard I. Fisher; Robert Coffman; Tim Mosmann; Arnold S. Freedman

Book ID: 108676377
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 339 KB
Volume: 146
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2009.07773.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of rituximab and bortezomi

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Por 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 1 views

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Phase I study of LY2469298, an Fc-engine

Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma

✍ Kensei Tobinai; Michinori Ogura; Yukio Kobayashi; Toshiki Uchida; Takashi Watana 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

Japanese phase II study of 90Y-ibritumom

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

✍ Kensei Tobinai; Takashi Watanabe; Michinori Ogura; Yasuo Morishima; Tomomitsu Ho 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Pixantrone dimaleate in combination with

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort

✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone

Relevance of monitoring metabolic reduct

Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study

✍ Ukihide Tateishi; Mitsuaki Tatsumi; Takashi Terauchi; Kenichi Ishizawa; Michinor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB